Diabetes Education News

BOSTON — Continuous glucose monitoring is becoming a mainstay of care for people with type 1 and type 2 diabetes, yet providers should be cautious about the technology’s application for people without diabetes looking for a “wellness” tool.

BOSTON — In this Healio video exclusive, Viral Shah, MD, discusses insulin delivery systems for patients with type 2 diabetes.

HOUSTON — A mobile health program that includes home visits from a health coach may be able to reduce racial and ethnic disparities and improve HbA1c for Black and Hispanic adults with type 2 diabetes, according to two speakers.

DALLAS —Behavioral weight management combined with diabetes education is linked to greater weight loss and a higher likelihood for diabetes remission for adults with new-onset type 2 diabetes, according to two speakers at ObesityWeek.

The 2023 Cardiometabolic Health Congress will return in-person to Boston with the latest updates spanning all aspects of cardiometabolic health, including CVD, diabetes, kidney disease, lipid and lifestyle management and obesity.

The FDA has approved an expanded indication of Boston Scientific’s spinal cord stimulation system that treats painful diabetic peripheral neuropathy, a complication of diabetes that often affects the lower extremities.

Children and adolescents with type 1 diabetes had an increase in time in range and reduction in HbA1c after starting a tubeless hybrid closed-loop insulin delivery system, according to study data

Higher initial glucose levels and increasing BMI over time could serve as predictors of progression from prediabetes to type 2 diabetes for children and adolescents, according to findings published in the Journal of the Endocrine Society.

Novo Nordisk has ended a clinical trial evaluating the impact of semaglutide on kidney function after the results from an interim analysis met certain pre-specified criteria, according to a company press release. To protect the integrity of the trial, Novo Nordisk will remain blinded to the results until the trial is completed, likely during the first half of 2024, according to the release. 

The majority of adults with diabetes say their diabetes team has never discussed the topic of mental health with them, even though most self-reported feelings of emotional distress, according to survey data published in Diabetic Medicine.